| Business Type | Exporter, Supplier, Retailer |
| Size | 153 mg / 1.7 mL vial |
| Type | Prescription oncology biologic,Prescription biologic therapy |
| Material | Teclistamab‑cqyv |
| Click to view more | |
Product Details
Packaged in a protective carton with prescribing information
Storage: Refrigerated at 2–8 °C (36–46 °F); protect from light; do not freeze
Supplied ready-to-use for subcutaneous injection
Tecvayli 153mg Injection contains the active substance Teclistamab. It is an anticancer medication classified as a bispecific monoclonal antibody.
Tecvayli Injection is used for the treatment of adult patients with relapsed or refractory multiple myeloma, a type of cancer affecting plasma cells in the bone marrow, who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Tecvayli works by targeting and binding to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognise and destroy the BCMA-expressing myeloma cells.
Inform your doctor before starting treatment with Tecvayli 153mg Injection, as it may lead to serious side effects such as cytokine release syndrome (CRS), neurotoxicities, and infections. Regular monitoring and prompt management of these conditions are crucial during therapy.
Make sure to inform your physician of all the medicines you are taking before starting treatment with Tecvayli 153mg Injection. Report any symptoms such as difficulty breathing, cough, fever, chest pain, weakness, or seizures to your doctor.
Uses of Tecvayli 153mg Injection
To treat adult patients with relapsed or refractory multiple myeloma (a type of cancer affecting plasma cells in the bone marrow) who have previously received at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Therapeutic Effects of Tecvayli 153mg Injection
Tecvayli 153mg Injection works by targeting and binding specifically to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognise and destroy the BCMA-expressing myeloma cells, thereby inhibiting their growth and proliferation.
Interaction of Tecvayli 153mg Injection with other drugs
Inform your healthcare professional about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products.
Certain medications interacting with Tecvayli 153mg Injection may reduce effectiveness by causing undesirable side effects.
More Information about Tecvayli 153mg Injection
- Store Tecvayli 153mg Injection in the refrigerator at 2°C to 8°C. Do not freeze.
- Keep out of sight and reach of children and pets.
- Store in the original container to protect from light.
- Monitor patients regularly for signs and symptoms of cytokine release syndrome (CRS) and neurological toxicities.
- Conduct regular blood tests to detect any abnormalities and other potential side effects, as directed by the healthcare provider.
How to consume Tecvayli 153mg Injection
A healthcare professional administers Tecvayli 153mg Injection via intravenous infusion. The infusion is given over a specified duration as per your doctor's treatment schedule. Do not self-administer the injection or alter the infusion schedule without consulting your healthcare provider.
Email: peptidevera@
